<DOC>
	<DOCNO>NCT01943318</DOCNO>
	<brief_summary>Liver cirrhosis represent worldwide health problem major cause mortality . Cirrhosis common end chronic alcohol abuse hepatitis C B virus infection . Patients cirrhosis vary degree compensate liver function , clinician need differentiate stable , compensated cirrhosis decompensated cirrhosis . It show various complication : portal hypertension , hepatocellular carcinoma , hepato-renal syndrome , etc . Thus , important information manage disease determine specific therapy . However , register-based study report Korea . The goal study describe natural history large number patient liver cirrhosis prospectively follow , identify predictor occurrence Hepatocellular carcinoma .</brief_summary>
	<brief_title>Boramae Hospital Liver Cirrhosis Patient Cohort Study</brief_title>
	<detailed_description>The investigator plan recruit patient liver cirrhosis , collect baseline clinical laboratory data . Biological test , endoscopy , liver ultrasonography ( include ARFI ) hepatic venous pressure gradient measurement perform do within 90 day prior inclusion . During visit , 20 ml blood collect freezing storage serum plasma , constitution DNA library . Monitoring : Patients regular surveillance blood test , liver ultrasonography medical consultation least every 6 month , periodic assessment esophageal , gastric varix portal hypertensive gastropathy ( every 1 year ) prevention rupture . An additional blood sample 20 ml take baseline every year order perform whole blood , serum , plasma , peripheral blood mononuclear cell DNA library ; Data standardize centralize single database . And alcoholic liver cirrhosis patient undergo liver biopsy polymerase chain reaction , western blot , immunohistochemistry RNA analysis . After measurement hepatic venous pressure gradient liver stiffness baseline non-selective beta-blocker ( NSBB , carvedilol ) initiate increase stepwise ( weekly ) systolic blood pressure remain &gt; 100 mmHg heart rate &lt; 60 . The maximum target dose carvedilol 25 mg/day . The hepatic venous pressure gradient response NSBB assess 6 week intake carvedilol . A hemodynamic response NSBB treatment define reduction hepatic venous pressure gradient &gt; =20 % compare baseline absolute value &lt; =12 mmHg . Compliance therapy monitor monitoring heart rate blood pressure clinical visit .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>Age â‰¥19years old Proven cirrhosis No previous hepatocellular carcinoma ( treat ) Signed informed consent serious associate shortterm life threaten disease ( except associate HIV viral infection liver disease ) liver focal lesion suggestive hepatocellular carcinoma patient guardianship pregnant woman inability regular monitoring , whatever reason</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Liver Cirrhosis</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
</DOC>